Palforzia for Peanut Allergy: A Narrative Review and Update on a Novel Immunotherapy
Grant Borne, Charles P Daniel, Maxwell J Wagner, Connor J Plaisance, Alexandra Nolen, Rucha A. Kelkar, Shahab Ahmadzadeh, Dariusz Myrcik, Sahar Shekoohi, Alan D. Kaye, Giustino Varrassi
Abstract
With Palforzia appearing as the first oral immunotherapy for patients with peanut allergy, the present investigation aims to summarize recent clinical trials, the mechanism of dosing, and the real-world usage of this novel therapy. Palforzia offers a new avenue for treating the human allergic response in previous immune modulation refractory patients or patients who have undergone immune environment sensitivity testing, which allows for more specialized treatment. Current studies are focusing on certain age groups that have been shown to be more receptive to treatment. Further, studies are tailoring oral immunotherapy treatment alongside other immune modulators to elicit greater targeted immune tolerance. With an increasing prevalence of patient allergies, many questions remain surrounding the optimization of therapies in reaching therapeutic goals. Overall, Palforzia offers a hopeful treatment for peanut-allergic patients to attenuate their immune response while furthering research in related therapies.